IPO registrations (S-1, F-1) · Registrants

TETRAPHASE PHARMACEUTICALS INC

SEC CIK
1373707 · filings on EDGAR ↗
Registration
Form S-1, first filed 2013-02-11, last 2013-11-04; 2 initial registrations, 4 amendments
Outcome
Final prospectus filed 2013-03-20; declared effective 2013-03-19
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
480 ARSENAL WAY, Watertown, MA 02472
EDGAR entity type
operating
Insiders and CEO pay
TETRAPHASE PHARMACEUTICALS INC on the corporate pages

Offering terms

Proposed price range
$8.00–$10.00 per share (S-1/A filed 2013-03-19)
Final price
$7.00 per share, below the range (424B4 filed 2013-03-20, an initial public offering)
Shares sold
10,714,286
Gross proceeds
$75,000,002 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol TTPH
Lead underwriters
Barclays; BMO Capital Markets
Syndicate
Stifel; JMP Securities; Needham & Company

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 12

FiledFormWhat it isName as filedEDGAR
2013-02-11S-1S-1 (registration)TETRAPHASE PHARMACEUTICALS INC0001193125-13-048887 ↗
2013-02-21S-1/AS-1/A (amendment)TETRAPHASE PHARMACEUTICALS INC0001193125-13-068739 ↗
2013-03-05S-1/AS-1/A (amendment)TETRAPHASE PHARMACEUTICALS INC0001193125-13-091764 ↗
2013-03-19S-1/AS-1/A (amendment)TETRAPHASE PHARMACEUTICALS INC0001193125-13-114713 ↗
2013-03-19EFFECTEFFECT (declared effective)TETRAPHASE PHARMACEUTICALS INC9999999995-13-000746 ↗
2013-03-20424B4424B4 (final prospectus)TETRAPHASE PHARMACEUTICALS INC0001193125-13-117520 ↗
2013-10-25S-1S-1 (registration)TETRAPHASE PHARMACEUTICALS INC0001193125-13-410084 ↗
2013-11-04S-1/AS-1/A (amendment)TETRAPHASE PHARMACEUTICALS INC0001193125-13-424016 ↗
2013-11-06S-1MEFS-1MEF (added securities)TETRAPHASE PHARMACEUTICALS INC0001193125-13-430932 ↗
2013-11-06EFFECTEFFECT (declared effective)TETRAPHASE PHARMACEUTICALS INC9999999995-13-003207 ↗
2013-11-07424B4424B4 (final prospectus)TETRAPHASE PHARMACEUTICALS INC0001193125-13-432969 ↗
2014-05-21EFFECTEFFECT (declared effective)TETRAPHASE PHARMACEUTICALS INC9999999995-14-001545 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-03-19S-1/Aregistration statement$8.00–$10.008,333,333-Nasdaq TTPH5primary document; range, price sentence, shares headline, proceeds computed, price outside the range dropped, cover names 5document ↗
2013-03-20424B4final prospectus$7.0010,714,286$75,000,002Nasdaq TTPH5primary document; price sentence, shares headline, proceeds table, cover names 5document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
AFEYAN NOUBARTenPercentOwner22013
BARUCH THOMAS RTenPercentOwner42013
Blume Frederick R.TenPercentOwner22013
BOHLIN GAREN GDirector82013–2019
CMEA Ventures VI GmbH & Co. KGTenPercentOwner42013
CMEA VENTURES VI LPTenPercentOwner42013
CMEA Ventures VI Management, L.P.TenPercentOwner42013
Cole Douglas G.Director42013
Collier David JTenPercentOwner42013
Enriquez JuanTenPercentOwner22013
EXCEL MEDICAL FUND LPTenPercentOwner22013
Excel Medical Ventures, LLCTenPercentOwner22013
Flagship Ventures 2007 General Partner LLCTenPercentOwner22013
Flagship Ventures Fund 2004 L PTenPercentOwner22013
Flagship Ventures Fund 2007, L.P.TenPercentOwner22013
Flagship Ventures General Partner LLCTenPercentOwner22013
FMR LLCOther; TenPercentOwnerOther62013–2015
Freund John GordonDirector; DirectorOther; Director,TenPercentOwner202013–2019
GAGE L PATRICKDirector182013–2020
Gullans Steven R. Ph.D.Director; Director,TenPercentOwner42013–2014
Handelsman Karl D.TenPercentOwner22013
Horn Patrick TaylorOfficerChief Medical Officer112013–2017
Howard Paul AnthonyTenPercentOwner22013
KANEKO YASUNORITenPercentOwner32013–2014
KANIA EDWIN M JRTenPercentOwner22013
Lubner David CharlesOfficer; Officer,TenPercentOwnerSVP and CFO132013–2015
Macdonald GuyDirector; Director,Officer; Director,Officer,TenPercentOwnerPresident and Chief Executive342013–2020
Mediphase (DP&UP) LLCTenPercentOwner22013
Mediphase II (Annex Fund) LLCTenPercentOwner22013
Mediphase II LLCTenPercentOwner22013
Mediphase II (Select Fund) LLCTenPercentOwner22013
Mediphase Venture Partners (DP&UP) Limited PartnershipTenPercentOwner22013
Mediphase Venture Partners II (Annex Fund) Limited PartnershipTenPercentOwner22013
MEDIPHASE VENTURE PARTNERS II LPDirector,TenPercentOwner; TenPercentOwner22013
Mediphase Venture Partners II (Select Fund) Limited PartnershipTenPercentOwner22013
Miller Lawrence G.TenPercentOwner22013
Myers AndrewTenPercentOwner12013
Petrillo EnricoTenPercentOwner22013
Ronn MagnusTenPercentOwner12013
Skyline Venture Management IV, LLCTenPercentOwner32013–2014
Skyline Venture Partners Qualified Purchaser Fund IV L PTenPercentOwner32013–2014
Sohail Faysal A.TenPercentOwner42013
Sutcliffe Joyce A.OfficerSenior Vice President, Biology72013–2014
Trias JoaquimTenPercentOwner22013
Watson James FTenPercentOwner42013
Webster LelandTenPercentOwner12013
Xiao Xiao-YiTenPercentOwner22013
THOMPSON JOHN CRAIGOfficerChief Operating Officer92014–2015
Wysenski NancyDirector72014–2019
HOFFMAN STEPHEN JTenPercentOwner12014
Chodakewitz JeffreyDirector72014–2019
Stahl Maria DOfficerCBO and General Counsel; See Remarks; SVP and General Counsel102015–2020
HENWOOD GERALDINEDirector62015–2019
Giroir L. Patrick Jr.Director; Other22015
Watt ChristopherOfficerSenior Vice President, Finance; SVP, Finance; VP, Finance72016–2020
Dumas JacquesOfficerChief ScientificOfficer112016–2019
Unninayar KamalamOfficerChief Financial Officer32017–2018
Tsai LarryOfficerChief Medical Officer42018–2019
Edwards Larry G.Director,Officer; OfficerChief Operating Officer; President and CEO; See Remarks52018–2020
ARMISTICE CAPITAL, LLCDirector,TenPercentOwner22020
Armistice Capital Master Fund Ltd.Director,TenPercentOwner; TenPercentOwner22020
Boyd StevenDirector,TenPercentOwner22020
Maher Illya KeithDirector12020
LA JOLLA PHARMACEUTICAL COTenPercentOwner32020
La Jolla Pharmaceutical Holdings, LLCTenPercentOwner12020
TTP Merger Sub, Inc.TenPercentOwner12020

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2020-01-28TETRAPHASE PHARMACEUTICALS INCPharmaceuticals$9,997,939$9,997,93911

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationTetraphase Pharmaceuticals Inc.MAState business registriesname and state
Business registrationTetraphase Pharmaceuticals Inc.MAState business registriesname and state
Business registrationTetraphase Pharmaceuticals, Inc.MAState business registriesname and state
Business registrationTetraphase Pharmaceuticals, Inc.MAState business registriesname and state
Business registrationTetraphase Pharmaceuticals, Inc.MAState business registriesname and state
Business registrationTETRAPHASE PHARMACEUTICALS, INC.MAState business registriesname and state
Business registrationTETRAPHASE PHARMACEUTICALS, INC.MAState business registriesname and state
Business registrationTETRAPHASE PHARMACEUTICALS, INC.MAState business registriesname and state
Business registrationTETRAPHASE PHARMACEUTICALS, INC.MAState business registriesname and state
ContractorTETRAPHASE PHARMACEUTICALS INCMANonprofit contractors (Form 990)name and state
Plan sponsorTETRAPHASE PHARMACEUTICALS, INC.MAForm 5500 (employee benefit plans)name and state
Federal award recipientTETRAPHASE PHARMACEUTICALS INCMAFederal spending (USAspending)name and state
Form D issuerTETRAPHASE PHARMACEUTICALS INCMAForm D private offeringsCIK (EXACT)
IPO registrantLyra Therapeutics, Inc.MAIPO registrations (S-1, F-1)same street address and ZIP code, 480 ARSENAL WAY 02472 (FUZZY: a shared address, not proof of a shared organization)
Lobbying clientTETRAPHASE PHARMACEUTICALSMAFederal lobbying (LDA)name and state
Lobbying clientTETRAPHASE PHARMACEUTICALSMAFederal lobbying (LDA)name and state
Paying companyTetraphase Pharmaceuticals, Inc.MAOpen Payments (drug and device company payments)name and state
Patent assigneeTetraphase Pharmaceuticals, Inc.MAPatents (USPTO)name and state
SEC filerTETRAPHASE PHARMACEUTICALS INCSEC filers (EDGAR)CIK (EXACT)
Trademark ownerTetraphase Pharmaceuticals, Inc.MATrademarks (USPTO)name and state

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, MA first:

More with this interest.

In other datasets, the same topic (Health) in MA:

Interests: Pharmaceutical Preparations · Health